Results 21 to 30 of about 2,048,259 (212)

Linezolid induces ring sideroblasts

Haematologica, 2013
Linezolid, an oxazolidinone antibiotic approved for the treatment of respiratory tract and skin infection caused by Gram-positive bacteria, is known to have mitochondrial toxicity.[1][1] Mitochondrial toxicity is explained by linezolid’s specific binding to mitochondrial ribosomes, leading ...
Christophe Willekens, Florent Dumezy, Thomas Boyer, Aline Renneville, Julien Rossignol, Céline Berthon, Angélique Cotteau-Leroy, Lotfi Mehiaoui, Bruno Quesnel, Claude Preudhomme   +9 more
doaj   +3 more sources

A case of MDS/MPN overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage [PDF]

Clinical Case Reports, 2023
Key Clinical Message No formal treatment guidelines for MDS/MPN‐RS‐T exist. With salient features such as anemia and thrombocytosis, management is individualized and aims to address anemia, thrombosis, and in some cases acquired von Willebrand's disease.
Hannah Cherniawsky, Habib Moshref Razavi
doaj   +2 more sources

Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts. [PDF]

Intern Med, 2022
Vitamin B6 (VB6) is essential to heme synthesis, and its deficiency can lead to anemia. VB6 deficiency anemia is typically microcytic, hypochromic, and sideroblastic.
Yasuda H, Hatano T, Honda T, Tsutsui M, Hattori N, Ando M, Komatsu N.   +6 more
europepmc   +2 more sources

An Active Isodicentric X Chromosome in a Case of Refractory Anaemia with Ring Sideroblasts Associated with Marked Thrombocytosis [PDF]

Case Reports in Genetics, 2014
Refractory anaemia with ring sideroblasts and marked thrombocytosis (RARS-T) is a provisional entity in the World Health Organization (WHO) classification.
Rosario M. Morales Camacho, Javier Sanchez, Irene Marcos Luque, Ricardo Bernal, Jose F Falantes, Jose A Pérez-Simón   +5 more
doaj   +2 more sources

Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review. [PDF]

Curr Oncol
Myelodysplastic neoplasms (MDS) with ring sideroblasts (RS) are diagnosed via bone marrow aspiration in the presence of either (i) ≥15% RS or (ii) 5–14% RS and an SF3B1 mutation.
Mortuza S, Chin-Yee B, James TE, Chin-Yee IH, Hedley BD, Ho JM, Saini L, Lazo-Langner A, Schenkel L, Bhai P, Sadikovic B, Keow J, Sangle N, Hsia CC.   +13 more
europepmc   +2 more sources

Splicing factor SF3B1 mutations and ring sideroblasts in myelodysplastic syndromes: a Brazilian cohort screening study

Revista Brasileira de Hematologia e Hemoterapia, 2016
Background: Myelodysplastic syndromes (MDS) comprise a group of malignant clonal hematologic disorders characterized by ineffective hematopoiesis and propensity for progression to acute myeloid leukemia.
Flávia Sacilotto Donaires, Felipe Martelli, Raquel de Melo Alves-Paiva, Silvia Maria Meira Magalhães, Ronald Feitosa Pinheiro, Rodrigo Tocantins Calado   +5 more
doaj   +3 more sources

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia. [PDF]

Hemasphere, 2021
Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation.
Delgado J, Voltz C, Stain M, Balkowiec-Iskra E, Mueller B, Wernsperger J, Malinowska I, Gisselbrecht C, Enzmann H, Pignatti F.   +9 more
europepmc   +2 more sources

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.

Blood, 2022
Luspatercept is an approved therapy for selected patients with lower risk myelodysplasia requiring transfusion despite erythropoiesis-stimulating agents, based on the early results of a randomized trial against placebo.
Zeidan AM, Platzbecker U, Garcia-Manero G, Sekeres MA, Fenaux P, DeZern AE, Greenberg PL, Savona MR, Jurcic JG, Verma AK, Verma AK, Mufti GJ, Buckstein R, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji RS.   +20 more
europepmc   +2 more sources

Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts. [PDF]

PLoS ONE, 2015
The presence of SF3B1 gene mutations is a hallmark of refractory anemia with ring sideroblasts (RARS). However, the mechanisms responsible for iron accumulation that characterize the Myelodysplastic Syndrome with ring sideroblasts (MDS-RS) are not ...
Mónica del Rey, Rocío Benito, Celia Fontanillo, Francisco J Campos-Laborie, Kamila Janusz, Talía Velasco-Hernández, María Abáigar, María Hernández, Rebeca Cuello, Daniel Borrego, Dionisio Martín-Zanca, Javier De Las Rivas, Ken I Mills, Jesús M Hernández-Rivas   +13 more
doaj   +3 more sources

Numerous ring sideroblasts in chronic neutrophilic leukemia [PDF]

Blood, 2021
72-year-old with anemia and bilateral lower-extremity edema for 2 months. Anemia had once been noted 5 years ago. Laboratory fi ndings showed white blood cells 31.08 3 10 9 /L (86% neutrophils, 1% myelocytes, 4% metamyelocytes, 1% monocytes, 8% lympho ...
Yi Feng, Weiying Feng
openaire   +3 more sources